^
Association details:
| Biomarker: | SPOP mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic, clinical characteristics, and treatment outcomes of patients with metastatic castration-sensitive prostate cancer with SPOP mutations: Analysis from the Kaiser Permanente Northern California Healthcare System.
Published date:
02/13/2023
Excerpt:
...we retrospectively identified 70 mCSPC patients with mutSPOP….Median PFS for CRPC patients who received 2nd line treatment with Abiraterone, or Enzalutamide was 15.3 mos.
DOI:
10.1200/JCO.2023.41.6_suppl.261
